Virios therapeutics announces plans to advance development of imc-2 as treatment for symptoms associated with long-covid

- placebo-controlled clinical proof of concept data expected in mid-2024 - - targeting initiation of imc-2 phase 2 program in 2h 2024 -

VIRI Ratings Summary

VIRI Quant Ranking